Safety and Feasibility of DopaCell transplantation in patients with Parkinson's disease

General Information
Clinical trials phase	Phase 1
Start date (estimated)	2023-12-22
Clinical feature	Label Parkinson's disease Link http://purl.obolibrary.org/obo/DOID_14330 Description A synucleinopathy that has_material_basis_in degeneration of the central nervous system that often impairs motor skills, speech, and other functions.; Xref MGI. OMIM mapping confirmed by DO. [SN].
Administrative Information
ICTRP weblink	https://trialsearch.who.int/Trial2.aspx?TrialID=IRCT20160704028786N2
Other study identifiers	Name IRCT20160704028786N2 Description (IRCT registration number) Name DOPASON study
Source weblink	https://en.irct.ir/trial/71062
Public contact	Email salahi13639@gmail.com Public email salahi13639@gmail.com First name Sarvenaz Last name Salahi Phone +98 21 2356 2000 Country Iran
Sponsors	Iranian academic center for education culture and research Shiraz University of Medical Sciences Iran University of Medical Sciences
Cells
Which differentiated cell type is used	Label dopaminergic neuron Link http://purl.obolibrary.org/obo/CL_0000700 Description A neuron that releases dopamine as a neurotransmitter.
Recruitment
Recruitment Status	Not yet recruiting
Estimated number of participants	4